CU20170168A7 - Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina - Google Patents

Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina

Info

Publication number: CU20170168A7
Authority: CU; Cuba
Prior art keywords: emtricitabina; pharmaceutical formulations; include tenofovir; tenofovir; pharmaceutically acceptable
Prior art date: 2015-06-30

Application number

CUP2017000168A

Other languages

English (en)

Spanish (es)

Inventor

Joanna M Koziara

Scott Mccallister

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-30

Filing date

2016-06-29

Publication date

2018-07-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20170168(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-29 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2018-07-05 Publication of CU20170168A7 publication Critical patent/CU20170168A7/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Biophysics (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CUP2017000168A 2015-06-30 2016-06-29 Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina CU20170168A7 (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562187113P	2015-06-30	2015-06-30
US201662298373P	2016-02-22	2016-02-22
US201662301429P	2016-02-29	2016-02-29
US201662317286P	2016-04-01	2016-04-01
PCT/US2016/040158 WO2017004244A1 (en)	2015-06-30	2016-06-29	Pharmaceutical formulations comprising tenofovir and emtricitabine

Publications (1)

Publication Number	Publication Date
CU20170168A7 true CU20170168A7 (es)	2018-07-05

Family

ID=56418608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CUP2017000168A CU20170168A7 (es)	2015-06-30	2016-06-29	Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina

Country Status (26)

Country	Link
US (3)	US20180177734A1 (pl)
EP (6)	EP4527467B1 (pl)
JP (3)	JP6667556B2 (pl)
KR (2)	KR102313668B1 (pl)
CN (2)	CN107847450A (pl)
AU (3)	AU2016287500B2 (pl)
BR (1)	BR112017027843A2 (pl)
CA (1)	CA2990210C (pl)
CL (1)	CL2017003320A1 (pl)
CO (1)	CO2017013293A2 (pl)
CU (1)	CU20170168A7 (pl)
DO (1)	DOP2017000306A (pl)
EA (1)	EA201792592A1 (pl)
EC (1)	ECSP17084331A (pl)
ES (5)	ES3007987T3 (pl)
HK (1)	HK1248547A1 (pl)
IL (1)	IL256364A (pl)
MA (1)	MA50541A (pl)
MX (1)	MX2017016806A (pl)
PE (1)	PE20180411A1 (pl)
PH (1)	PH12017502431A1 (pl)
PL (5)	PL4070788T3 (pl)
PT (4)	PT4070788T (pl)
SI (4)	SI3607939T1 (pl)
SV (1)	SV2017005601A (pl)
WO (1)	WO2017004244A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA030003B1 (ru)	2012-12-21	2018-06-29	Джилид Сайэнс, Инк.	Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
JP7381190B2 (ja)	2014-12-26	2023-11-15	エモリー・ユニバーシテイ	Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2017083304A1 (en)	2015-11-09	2017-05-18	Gilead Sciences, Inc.	Therapeutic compositions for treatment of human immunodeficiency virus
CN116730920A (zh)	2017-02-17	2023-09-12	文涵治疗有限公司	Ag-10的制备方法、其中间体及其盐
WO2018153977A1 (en) *	2017-02-24	2018-08-30	Hexal Ag	Stable composition of tenofovir alafenamide
AU2018239257B2 (en) *	2017-03-20	2023-09-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	HIV post-exposure prophylaxis
RU2662160C9 (ru)	2017-07-03	2018-10-22	Александрович Иващенко Андрей	Комбинированный лекарственный препарат для терапии вирусных инфекций
PT3706762T (pt)	2017-12-07	2024-12-05	Univ Emory	N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
TWI817999B (zh)	2018-03-23	2023-10-11	美商文涵治療有限公司	使用ag10治療ttr澱粉樣沉積症之方法
SI3836920T1 (sl) *	2018-08-17	2026-02-27	Eidos Therapeutics, Inc.	Formulacije AG10
CN111096954B (zh) *	2018-10-29	2022-09-16	江苏豪森药业集团有限公司	一种用于抗病毒感染的药物组合物及制备方法
JP2022538338A (ja) *	2019-07-03	2022-09-01	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN110251476B (zh) *	2019-08-01	2022-08-09	海思科制药(眉山)有限公司	一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) *	2019-12-31	2020-03-27	常州恒邦药业有限公司	一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) *	2020-02-19	2021-05-21	台灣森本生物科技開發股份有限公司	含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN117653644A (zh) *	2022-08-24	2024-03-08	安徽贝克制药股份有限公司	包含恩曲他滨、替诺福韦和利匹韦林的药物组合物
WO2024211882A1 (en) *	2023-04-07	2024-10-10	Navinta, Llc	Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN117338733B (zh) *	2023-10-12	2024-05-28	杭州和泽坤元药业有限公司	一种富马酸替诺福韦二吡呋酯片及其制备工艺
WO2025229473A1 (en) *	2024-05-01	2025-11-06	Lupin Limited	Tenofovir alafenamide compositions
CN119174735A (zh) *	2024-09-03	2024-12-24	安徽贝克生物制药有限公司	一种含利匹韦林的复方片及制备方法
CN119139247A (zh) *	2024-09-05	2024-12-17	安徽贝克生物制药有限公司	一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020119443A1 (en)	2000-07-21	2002-08-29	Gilead Sciences, Inc.	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
DK1583542T3 (da)	2003-01-14	2008-09-22	Gilead Sciences Inc	Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
EP2393485B1 (en)	2009-02-06	2015-07-29	Gilead Sciences, Inc.	Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir
ES2608871T5 (es)	2011-08-16	2024-04-04	Gilead Sciences Inc	Alafenamide hemifumarate de tenofovir
AU2013204727A1 (en)	2012-02-03	2013-08-22	Gilead Sciences, Inc.	Therapeutic compounds
JP2016528240A (ja) *	2013-08-14	2016-09-15	ラシオファルムゲーエムベーハー	ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
CZ2013985A3 (cs) *	2013-12-09	2015-06-17	Zentiva, K.S.	Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (pl) *	2014-06-20	2018-06-23

2016
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 ES ES23162978T patent/ES3007987T3/es active Active
- 2016-06-29 HK HK18108248.3A patent/HK1248547A1/zh unknown
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active Active
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active Active
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 EP EP24216441.6A patent/EP4527467B1/en active Active
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/xx unknown
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 EP EP23162978.3A patent/EP4233846B1/en active Active
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en not_active Ceased
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 CN CN202411894523.5A patent/CN119606990A/zh active Pending
- 2016-06-29 PL PL23162978.3T patent/PL4233846T3/pl unknown
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
2025
- 2025-02-07 US US19/048,549 patent/US20250281412A1/en active Pending

Also Published As

Publication number	Publication date
KR102121329B1 (ko)	2020-06-17
MX2017016806A (es)	2018-05-07
PL4070787T3 (pl)	2023-07-24
PL3607939T3 (pl)	2022-11-07
PL3316868T3 (pl)	2020-10-19
ECSP17084331A (es)	2018-01-31
PT4070787T (pt)	2023-05-22
MA50541A (fr)	2021-04-07
EA201792592A1 (ru)	2018-06-29
CA2990210A1 (en)	2017-01-05
EP3607939A1 (en)	2020-02-12
PH12017502431A1 (en)	2018-07-02
CN119606990A (zh)	2025-03-14
US20170000807A1 (en)	2017-01-05
PT4070788T (pt)	2023-06-06
KR20200067937A (ko)	2020-06-12
EP4527467A3 (en)	2025-05-21
US20180177734A1 (en)	2018-06-28
EP4070787A1 (en)	2022-10-12
EP4233846B1 (en)	2024-12-04
SV2017005601A (es)	2018-05-04
JP2018519297A (ja)	2018-07-19
HK1248547A1 (zh)	2018-10-19
JP6978534B2 (ja)	2021-12-08
EP4233846A3 (en)	2023-10-04
IL256364A (en)	2018-02-28
BR112017027843A2 (pt)	2018-09-04
ES2925246T3 (es)	2022-10-14
JP2020079304A (ja)	2020-05-28
EP4527467B1 (en)	2026-03-18
JP2021185188A (ja)	2021-12-09
US20250281412A1 (en)	2025-09-11
WO2017004244A1 (en)	2017-01-05
AU2019210558A1 (en)	2019-08-15
EP4233846C0 (en)	2024-12-04
ES2786549T3 (es)	2020-10-13
PT3316868T (pt)	2020-04-21
CA2990210C (en)	2021-01-12
ES2945896T3 (es)	2023-07-10
EP4070787B1 (en)	2023-03-01
ES3007987T3 (en)	2025-03-21
SI3607939T1 (sl)	2022-10-28
AU2021202009A1 (en)	2021-04-29
EP4233846A2 (en)	2023-08-30
EP4070788B1 (en)	2023-03-22
PL4233846T3 (pl)	2025-03-24
CN107847450A (zh)	2018-03-27
AU2021202009B2 (en)	2023-04-13
AU2016287500A1 (en)	2018-01-18
DOP2017000306A (es)	2018-01-15
ES2945345T3 (es)	2023-06-30
CL2017003320A1 (es)	2018-07-13
PL4070788T3 (pl)	2023-07-10
EP4527467A2 (en)	2025-03-26
EP3316868A1 (en)	2018-05-09
EP3607939B1 (en)	2022-06-01
AU2019210558B2 (en)	2021-04-22
JP6667556B2 (ja)	2020-03-18
EP3316868B1 (en)	2020-02-19
EP4070788A1 (en)	2022-10-12
SI4070788T1 (sl)	2023-06-30
KR20180021134A (ko)	2018-02-28
SI4070787T1 (sl)	2023-07-31
KR102313668B1 (ko)	2021-10-19
PT3607939T (pt)	2022-09-12
SI3316868T1 (sl)	2020-04-30
AU2016287500B2 (en)	2019-05-02
CO2017013293A2 (es)	2018-05-31
PE20180411A1 (es)	2018-03-01

Publication	Publication Date	Title
CU20170168A7 (es)	2018-07-05	Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
IL264210A (en)	2019-02-28	High-strength oral cannabinoid dosage forms
EP4045480A4 (en)	2023-11-22	PHARMACEUTICAL FORMULATIONS
MX2017016802A (es)	2018-09-06	Formulaciones farmaceuticas.
IL264065A (en)	2019-01-31	Oral gastroretentive formulations and uses thes thereof
PH12016501841A1 (en)	2017-01-09	Immunosuppressant formulation
HUP1700253A1 (hu)	2019-01-28	Szilárd orális gyógyszerkészítmények
MA55015A (fr)	2021-12-29	Formulations pharmaceutiques
ZA202006570B (en)	2021-09-29	Pharmaceutical formulations
MX2018005358A (es)	2018-06-06	Comprimido de dosis alta que contiene mesalazina optimizado.
EP3746080A4 (en)	2021-11-17	PHARMACEUTICAL FORMULATIONS
EA201991286A1 (ru)	2019-10-31	Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX385513B (es)	2025-03-18	Composiciones farmaceuticas que comprenden safinamida.
SG11202010792TA (en)	2020-11-27	Improved pharmaceutical formulations
EP3697393A4 (en)	2021-10-13	DOSAGE FORMS
EP3651800C0 (en)	2024-04-10	HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS
EA201991007A1 (ru)	2019-08-30	Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CR20170601A (es)	2018-02-28	Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
EP3880171C0 (en)	2023-06-07	IBUPROFEN CONTAINING ORAL PHARMACEUTICAL FORMULATION
ZA201804275B (en)	2023-04-26	Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
HUE056233T2 (hu)	2022-02-28	Ibuprofén készítmények közvetlen orális beadásra
JOP20170198A1 (ar)	2019-06-30	صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CY1123966T1 (el)	2022-05-27	Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας
EP3955907A4 (en)	2022-12-28	PHARMACEUTICAL FORMULATIONS CONTAINING P2Y14 ANTAGONISTS
TR201721065A2 (tr)	2019-07-22	Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar